Clinical Trials Browser

Interventional × Has results × ceritinib × Clear all

NCT03737994 2026-04-07

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT01828112 2025-02-07

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Phase 3 Completed

231 enrolled 33 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Phase 3 Completed

376 enrolled 34 charts 2 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02513667 2023-02-03

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Phase 2 Terminated

14 enrolled 12 charts

ALK-positive Non-small Cell Lung Cancer

NCT02186821 2021-04-08

SIGNATURE

Phase 2 Terminated

47 enrolled 13 charts

LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Hematologic Neoplasms

NCT02450903 2021-03-30

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Phase 2 Completed

20 enrolled 12 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02276027 2020-12-16

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

66 enrolled 18 charts

Adenocarcinoma of Lung

NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Phase 1 Completed

83 enrolled 30 charts

CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

NCT02336451 2020-04-21

Ascend-7

Phase 2 Completed

156 enrolled 39 charts

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Phase 2 Terminated

1 enrolled 7 charts

Noonan Syndrome 6, Melanoma

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Phase 2 Terminated

22 enrolled 16 charts

CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

NCT01685138 2019-03-26

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Phase 2 Completed

124 enrolled 18 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01283516 2019-03-15

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Phase 1 Completed

304 enrolled 37 charts

Carcinoma, Non-Small-Cell Lung

NCT02040870 2019-02-20

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Phase 1/2 Completed

103 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01685060 2017-06-19

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Phase 2 Completed

140 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung